AstraZeneca gets FDA orphan drug status for Imfinz plus tremelimumab to treat hepatocellular carcinoma

Imfinz plus tremelimumab has secured FDA orphan drug designation to treat hepatocellular carcinoma (Credit: AstraZeneca)